Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced the presentation of eleven abstracts covering research in amyotrophic lateral sclerosis (ALS) at the 2025 Muscular Dystrophy Association ...

Roche and Zealand reason petrelintide could deliver weight loss comparable to glucagon-like peptide 1 (GLP-1) receptor ...

Profits and losses for petrelintide and the petrelintide/CT-388 combination will be shared on a 50:50 basis in the U.S. and Europe, while Zealand will be eligible to receive tiered double-digit ...

MariTide’s opportunity in diabetes should not be ignored. In addition to reducing weight by 17%, it reduced HbA1c up to 2.2% ...

Roche is doubling down on competing for a slice of the rapidly growing GLP-1 pie. The Swiss pharma giant announced a deal worth up to $5.3 billion on Wednesday with Danish drugmaker Zealand Pharma to ...

aspects of Brainstorm's Phase 3b clinical trial for NurOwn®, its investigational therapy for amyotrophic lateral sclerosis (ALS). BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer ...

An EASE 4 phase 3b trial is also planned to assess long-term ... that in the last six months have reported two positive phase 3 trials for two separate programs aimed at changing the lives of ...

The treatment also showed a favorable safety profile for older patients with the disease. Another phase 3b clinical trial called STRENGTH also showed that a 1-time intrathecal infusion of onasemnogene ...

Amgen’s $400 million eczema drug candidate has recorded two more phase 3 victories. The data drops provide more evidence that ...

In the second trial, which was open label, 95.6% of participants who switched to DOR/ISL maintained viral suppression ...